| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | CTAG1A |
| Uniprot No | P78358 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-180aa |
| 氨基酸序列 | MQAEGRGTGGSTGDADGPGGPGIPDGPGGNAGGPGEAGATGGRGPRGAGA ARASGPGGGAPRGPHGGAASGLNGCCRCGARGPESRLLEFYLAMPFATPM EAELARRSLAQDAPPLPVPGVLLKEFTVSGNILTIRLTAADHRQLQLSIS SCLQQLSLLMWITQCFLPVFLAQPPSGQRR |
| 预测分子量 | 48 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是三篇与CTAG1A(又称NY-ESO-1)重组蛋白相关的模拟参考文献及摘要概括(基于公开研究主题整理，非真实文献)：
---
1. **文献名称**: *Recombinant CTAG1A Protein Expression in E. coli and Its Application in Cancer Immunotherapy*
**作者**: Smith JR, Lee H, Chen W
**摘要**: 本研究报道了在大肠杆菌系统中高效表达和纯化重组CTAG1A蛋白的方法，验证了其免疫原性，并证明该蛋白可诱导特异性T细胞反应，为癌症疫苗开发提供实验基础。
2. **文献名称**: *CTAG1A as a Serum Biomarker: Development of a Recombinant Protein-Based ELISA for Cancer Diagnosis*
**作者**: Gonzalez M, Tanaka K, Müller P
**摘要**: 通过重组CTAG1A蛋白开发了一种新型ELISA检测技术，用于检测多种癌症患者血清中的抗CTAG1A抗体，结果显示其在卵巢癌和黑色素瘤中敏感性和特异性均超过80%，提示其作为诊断标志物的潜力。
3. **文献名称**: *Structural and Functional Characterization of Recombinant CTAG1A for TCR-T Cell Therapy*
**作者**: Wang Y, Rosenberg SA, Lu YC
**摘要**: 利用哺乳动物表达系统获得高纯度CTAG1A重组蛋白，解析其晶体结构并验证其与T细胞受体(TCR)的特异性结合，为优化TCR-T细胞治疗实体瘤提供了分子机制依据。
---
**注**：以上文献信息为示例性概括，实际研究需参考真实发表的论文(可通过PubMed或Google Scholar搜索“CTAG1A/NY-ESO-1 recombinant protein”获取)。
**Background of CTAG1A Recombinant Protein**
CTAG1A (Cancer-Testis Antigen Family 1A), also known as NY-ESO-1. is a member of the cancer-testis antigen (CTA) family, which comprises proteins predominantly expressed in germline cells and aberrantly re-expressed in various malignancies. Discovered in the late 1990s, CTAG1A has garnered significant attention due to its immunogenic properties and restricted expression profile, making it a promising target for cancer immunotherapy.
The gene encoding CTAG1A is located on chromosome Xq28 and shares homology with the LAGE (L antigen) family. The protein is characterized by a conserved structure with multiple epitopes recognized by T cells and antibodies, facilitating its role in immune recognition. In normal tissues, CTAG1A expression is largely confined to immune-privileged sites such as the testis (spermatogonia) and placenta, minimizing off-target immune responses. However, in cancers—including melanoma, lung, ovarian, and bladder carcinomas—CTAG1A is frequently overexpressed due to epigenetic dysregulation, serving as a tumor-associated antigen.
Recombinant CTAG1A protein is produced via genetic engineering in heterologous systems (e.g., *E. coli* or mammalian cells) to ensure high purity and antigenic fidelity. It is widely utilized in research and clinical applications, such as serological assays for detecting anti-CTAG1A antibodies in patient sera, in vitro T-cell activation studies, and vaccine development. Its strong immunogenicity has driven clinical trials exploring CTAG1A-targeted vaccines, adoptive T-cell therapies, and checkpoint inhibitor combinations, aiming to enhance anti-tumor immunity.
Overall, CTAG1A recombinant protein represents a critical tool for understanding tumor immunology and advancing personalized cancer therapies, bridging molecular biology and translational oncology.
×
